428 related articles for article (PubMed ID: 28668293)
1. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).
Wein L; Loi S
Breast; 2017 Aug; 34 Suppl 1():S27-S30. PubMed ID: 28668293
[TBL] [Abstract][Full Text] [Related]
2. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
5. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Axelrod ML; Nixon MJ; Gonzalez-Ericsson PI; Bergman RE; Pilkinton MA; McDonnell WJ; Sanchez V; Opalenik SR; Loi S; Zhou J; Mackay S; Rexer BN; Abramson VG; Jansen VM; Mallal S; Donaldson J; Tolaney SM; Krop IE; Garrido-Castro AC; Marotti JD; Shee K; Miller TW; Sanders ME; Mayer IA; Salgado R; Balko JM
Clin Cancer Res; 2020 Nov; 26(21):5668-5681. PubMed ID: 32826327
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint blockade in the treatment of breast cancer: current status and future directions.
Wein L; Luen SJ; Savas P; Salgado R; Loi S
Br J Cancer; 2018 Jul; 119(1):4-11. PubMed ID: 29808015
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
9. AKT1
Kabraji S; Solé X; Huang Y; Bango C; Bowden M; Bardia A; Sgroi D; Loda M; Ramaswamy S
Breast Cancer Res; 2017 Aug; 19(1):88. PubMed ID: 28764807
[TBL] [Abstract][Full Text] [Related]
10. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
12. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z
Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Balko JM; Giltnane JM; Wang K; Schwarz LJ; Young CD; Cook RS; Owens P; Sanders ME; Kuba MG; Sánchez V; Kurupi R; Moore PD; Pinto JA; Doimi FD; Gómez H; Horiuchi D; Goga A; Lehmann BD; Bauer JA; Pietenpol JA; Ross JS; Palmer GA; Yelensky R; Cronin M; Miller VA; Stephens PJ; Arteaga CL
Cancer Discov; 2014 Feb; 4(2):232-45. PubMed ID: 24356096
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
[TBL] [Abstract][Full Text] [Related]
16. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
Miyashita M; Sasano H; Tamaki K; Chan M; Hirakawa H; Suzuki A; Tada H; Watanabe G; Nemoto N; Nakagawa S; Ishida T; Ohuchi N
Breast Cancer Res Treat; 2014 Dec; 148(3):525-34. PubMed ID: 25395319
[TBL] [Abstract][Full Text] [Related]
18. Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer.
McArthur H
Oncology (Williston Park); 2019 Apr; 33(4):137-40. PubMed ID: 30990566
[No Abstract] [Full Text] [Related]
19. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
20. PIM1: a promising target in patients with triple-negative breast cancer.
Zhao W; Qiu R; Li P; Yang J
Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
